Efficacy News and Research

RSS

Study explores safety and efficacy of scoop and run approach in Philadelphia

A new study from the Perelman School of Medicine at the University of Pennsylvania has found no significant difference in adjusted overall survival rates between gunshot and stabbing (so-called penetrating trauma injuries) victims in Philadelphia whether they were transported to the emergency department by the police department or the emergency medical services division of the fire department.

3 Jan 2014

Study shows link between nurse fatigue and clinical decision regret

Fatigued nurses are more likely to express concern that they made a wrong decision about a patient's care, according to a study in the January issue of American Journal of Critical Care (AJCC).

3 Jan 2014

Cerenis' Phase IIb CHI-SQUARE study fails to meet primary endpoint in post-ACS patients

Cerenis Therapeutics, the biopharmaceutical company, today announced that its Phase IIb CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis REgression?) study did not reach its primary endpoint in post-Acute Coronary Syndrome patients.

2 Jan 2014

Research confirms superior antitumor activity of novel anticancer agent FL118

A team led by Fengzhi Li, PhD, of Roswell Park Cancer Institute has reported significant new findings regarding the chemical structure of the novel anticancer agent FL118. The research, which included comparative analysis of the agent and several similar compounds, confirms the broad, superior antitumor activity of FL118 and suggests promising directions for further studies.

2 Jan 2014

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Amgen and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).

2 Jan 2014

Kessler Foundation to conduct pilot study on improving memory, function in MS patients

Kessler Foundation has been awarded a new grant by the National Multiple Sclerosis Society for a pilot study of memory and learning difficulties in individuals with MS. Scientists will test the effectiveness of using of self-generated learning in a treatment intervention to improve memory and functional performance.

1 Jan 2014

Veloxis Pharmaceuticals seeks FDA approval to market Envarsus for prevention of organ rejection

Veloxis Pharmaceuticals A/S, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Envarsus (formerly LCP-Tacro) for the prevention of organ rejection in kidney transplant recipients.

30 Dec 2013

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Genzyme, a Sanofi company, announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.

30 Dec 2013

Researchers develop a class of compounds that may help eradicate Chagas disease

A team of researchers from Canada has developed a class of compounds which may help eradicate a neglected tropical disease that is currently hard to kill in its chronic form. The research was published ahead of print in Antimicrobial Agents and Chemotherapy.

27 Dec 2013

Fluidigm announces universal sample prep workflow for single-cell DNA sequencing

Fluidigm Corporation today announced a universal sample prep workflow for single-cell DNA sequencing that runs on its C1TM Single-Cell Auto Prep System. This workflow streamlines targeted, whole exome and whole genome sequencing in heterogeneous cell populations and enables researchers to discover and screen somatic mutations, such as SNP, small indels, and translocations.

24 Dec 2013

Genotyping strategy could boost celiac screening efficacy

Genotyping for human leukocyte antigen followed by biopsy is a sensitive strategy for detecting histopathologic lesions in the close relatives of people with celiac disease, research indicates.

24 Dec 2013

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Nearly 3.3 billion people, a little less than half of our world’s population, are at risk of malaria, TB and what we call “neglected tropical diseases”—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.

24 Dec 2013

Researchers identify potential therapy for meibomian gland dysfunction

Meibomian gland dysfunction is the leading cause of dry eye disease, which affects tens of millions of Americans. However, there is no FDA-approved treatment for MGD. Researchers from the Schepens Eye Research Institute/Massachusetts Eye and Ear and Harvard Medical School have just identified a potential therapy.

24 Dec 2013

Preoperative antibiotics within two hours of cardiac surgery decrease risk of developing SSIs

A new study found preoperative antibiotic therapy administered within two hours of cardiac surgery decreased the risk of developing surgical site infections (SSIs) significantly. The study was published in the January issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

23 Dec 2013

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.

23 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

TaiGen Biotechnology Company, Limited today announced that the U.S. Food and Drug Administration has granted nemonoxacin (Taigexyn) Qualified Infectious Disease Product and Fast Track designations for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

23 Dec 2013

Icahn School of Medicine receives $1.3M grant to build collaborative research infrastructure for stroke center

The Icahn School of Medicine at Mount Sinai joins a top-flight network of 25 regional stroke centers announced by the National Institute of Health that will focus on prevention, treatment, and recovery from stroke.

23 Dec 2013

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

Both real and sham weekly acupuncture treatments eased hot flashes and other side effects of anticancer drug treatment in a small, preliminary study of breast cancer patients, Baltimore researchers have found.

23 Dec 2013

Efficacy News and Research

Study explores safety and efficacy of scoop and run approach in Philadelphia

Study shows link between nurse fatigue and clinical decision regret

Cerenis' Phase IIb CHI-SQUARE study fails to meet primary endpoint in post-ACS patients

Research confirms superior antitumor activity of novel anticancer agent FL118

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Kessler Foundation to conduct pilot study on improving memory, function in MS patients

Veloxis Pharmaceuticals seeks FDA approval to market Envarsus for prevention of organ rejection

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Researchers develop a class of compounds that may help eradicate Chagas disease

Fluidigm announces universal sample prep workflow for single-cell DNA sequencing

Genotyping strategy could boost celiac screening efficacy

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Researchers identify potential therapy for meibomian gland dysfunction

Preoperative antibiotics within two hours of cardiac surgery decrease risk of developing SSIs

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

Icahn School of Medicine receives $1.3M grant to build collaborative research infrastructure for stroke center

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News